Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conferenceseries Ltd: World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Previous Speakers

Vladimir Torchilin

Vladimir Torchilin

Northeastern University USA

Matthew N Bahr

Matthew N Bahr

Glaxo Smith Kline USA

Minjun Chen

Minjun Chen

US Food and Drug Administration USA

Damon Smith

Damon Smith

founder and CEO of Altus Formulation Canada

Stefan Bughi

Stefan Bughi

Rancho Los Amigos National Rehabilitation Center USA

Volkmar Weissig

Volkmar Weissig

World Mitochondria Society USA

Yingqing Ran

Yingqing Ran

Genentech Inc. USA

Reinhard Gabathuler

Reinhard Gabathuler

Bioasis Technologies Inc Canada

Pharma Congress 2018

Sessions/Tracks

Conference Series Ltd invites all the participants across the globe to attend 18th World Pharma Congress during October 18-19, 2018 Warsaw, Poland, which includes prompt keynote presentations, oral talks, poster presentations and exhibitions. Pharma Congress 2018 is specially designed cluster Pharma conference. The main theme of Pharma conferences is “Challenges and Opportunities in Transforming the Pharma Industry". The Impact of developing and Marketing Drugs, its Registration & Approval” which covers a wide range of critically important sessions. 

Track 1: Pharmaceutical Sciences

Disease is the enemy of mankind, which affects part or all of organism.  Efforts to cure or improve the health condition against disease lead a remarkable improvement in pharmaceutical sciences. Pharmaceutical science is a wide range of combinations of scientific disciplines that contribute to the discovery and development of new drugs and therapies. Advancements in the branches of pharmaceutical sciences enhance the development of new reliable entities. Every aspect of the pharmaceutical science deals with the drug design, drug action, drug delivery, and drug disposition. According to the 2015 EU Industrial R&D Investment Scoreboard the pharmaceutical and biotechnology sector amounts to 18.2% of total business R&D expenditure worldwide. On the other side Europe drug manufacturing is 225000 €millions and exports were 361500 €millions. Europe spent 31,500 €millions on R&D in 2015 while US spent 47,061€millions.

Related Pharmaceutical EventsPharmaceutical Conferences

Related Societies

International Biopharmaceutical AssociationEuropean Biopharmaceutical EnterprisesPharmaceutical Society of AustraliaCanadian Pharmacists AssociationPharmaceutical Group of the European Union (PGEU), AACP – American Association of Colleges in Pharmacy, Royal Pharmaceutical Society, Pharmaceutical society of Australia, National Pharmacy Association, Canadian Pharmacists Association, European Pharmaceutical Union (EPU)

Track 2: Drug Discovery and Research

Persistent innovative development is one of the eminent characters of pharmaceutical industry. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting in an abundant knowledge of the mechanisms driving drug discovery and development. The invention of new medicines and the improvement of existing drugs constitute the development firms in this industry. The occasional triumph of creating a novel drug therapy in an area with no prior treatments counts among the pharmaceutical industry’s most defining hallmarks. Germany is forecast to have highest increase in market value at € 11.4bn. Novartis is forecast to reduce its R&D spending, from $10.5bn in 2020 to only $9.2bn in 2022. Of the top 20, Celgene and Regeneron are forecast to grow their R&D expenses most rapidly, with R&D spend forecast to increase 11% per year until 2022. Overall, total R&D spends is expected to increase by 2.8% each year, reaching $182bn in 2022.

 

Related Pharmaceutical EventsPharmaceutical Conferences

Related Societies

National Pharmacy AssociationDrug Discovery and Development Interface (DDDI)Royal Pharmaceutical Society (RPS)International Pharmaceutical Federation (FIP)European Association of Employed Community Pharmacists in Europe (EPhEU), AACP – American Association of Colleges in Pharmacy, Royal Pharmaceutical Society, Pharmaceutical society of Australia, National Pharmacy Association, Canadian Pharmacists Association, European Pharmaceutical Union (EPU)

Track 3: Drug Therapy

Pharmacotherapy deals in administering pharmaceutical drugs distinguishing from therapy using surgery, radiation, movement or other methods. Drug therapy complies patient care with various types of pharmaceutical drugs ensuring the safe, appropriate and economical use. North America is expected to account for more than half the therapeutic drug monitoring market share in 2015. It is the prime market for therapeutic drug monitoring. The market in Europe on the other hand is growing at a slower rate. Therapeutic Drug Monitoring Market’s worth is expected 2.55 Billion USD by 2020 globally.

Related Pharmaceutical EventsPharmaceutical Conferences

Related Societies

Therapeutic Goods Administration (TGA)American Tinnitus AssociationAACP – American Association of Colleges in Pharmacy, Royal Pharmaceutical Society, Pharmaceutical society of Australia, National Pharmacy Association, Canadian Pharmacists Association, European Pharmaceutical Union (EPU), Pharmaceutical Group of the European Union (PGEU)European Association of Employed Community Pharmacists in Europe (EPhEU),

Track 4: Innovations In Drug Development

Drug development involves enormous methods and development procedure to attain therapeutic effective level. Emerging new pharmaceutical formulation is a persistent process with utilization of abundant knowledge of pharmaceutics. Considering all characteristics of substances used, and their behavior towards formulations need more innovative approach of drug development. The global market value for drug development technologies market share was about 30% in 2015 valued at $18 billion followed by Bio analytical Assays or instruments by about $14 billion. Innovative formulations are estimated to have contributed to 73%. To develop a new pharmaceutical formulation and to conduct clinical trials it cost at € 1,926 million in 2016.

Related Pharmaceutical EventsPharmaceutical Conferences

Related Societies

International Pharmaceutical Federation (FIP)European Association of Employed Community Pharmacists in Europe (EPhEU)European Pharmaceutical UnionPharmaceutical Society of Australia, AACP – American Association of Colleges in Pharmacy, Royal Pharmaceutical Society, Canadian Pharmacists Association, European Pharmaceutical Union (EPU), Regulatory Affairs Professionals Society (RAPS), Association of Clinical Research Organizations

Track 5: Drug Delivery Systems

To obtain a required therapeutic effect, type of formulation technology and system for transporting drug are the important variables. Drug delivery technologies alter the drug release profiles, absorption, distribution, and elimination of product for the safety efficacy. Developing new avenues for drug delivery vehicles reported promising results. The practice of drug delivery has changed dramatically in the past few decades and even greater changes are anticipated in the near future. The global drug delivery technology market is projected to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% during the forecast period. This market is segmented based on route of administration, facility of use, and region.

Related Pharmaceutical EventsPharmaceutical Conferences

Related Societies

International Pharmaceutical Federation (FIP)European Association of Employed Community Pharmacists in Europe (EPhEU)European Pharmaceutical UnionAACP – American Association of Colleges in Pharmacy, Royal Pharmaceutical Society, Pharmaceutical society of Australia, National Pharmacy Association, Canadian Pharmacists Association, European Pharmaceutical Union (EPU)

 Track 6: Pharmaceutical Formulations

Pharmaceutical formulations is extensive procedure involving  characterization of a drug's physical, chemical, and mechanical properties in order to choose what other ingredients (excipients) should be used in the preparation and resulting a safe and efficacy product. Modern pharmaceutical formulation is expanding its sector with technology and innovation to formulate eminent result oriented formulations. The global pharmaceutical excipients market is projected to reach USD 8.1 Billion in 2021 at a CAGR of 6.1% in the forecast period 2016 to 2021. The rising demand for new drug delivery systems, greater understanding of the functional benefits of excipients, growing pharmaceutical industry, and patent expiries of several blockbuster drugs are positively impacting the overall growth of the market.

Related Pharmaceutical EventsPharmaceutical Conferences

Related Societies

European Association of Employed Community Pharmacists in Europe (EPhEU)European Pharmaceutical Union, AACP – American Association of Colleges in Pharmacy, Royal Pharmaceutical Society, Pharmaceutical society of Australia, National Pharmacy Association, Canadian Pharmacists Association, European Pharmaceutical Union (EPU)International Pharmaceutical Federation (FIP)Drug Discovery and Development Interface (DDDI)

Track 7: Advances In Clinical Trials

Clinical trials are the clinical investigation of a drug that administered or dispensed to, or used involving one or more human subjects. Clinical trials are the major parameter for the approval of drug, as they mainly deals with the effectiveness and safety.  Clinical trials play a vital role in the development of new drug entity as it subjected to various phases for approval. Advancements in clinical trials enhance the drug development process by means of reducing time duration, sometimes the cost. The success rate of Phase II trials that proceed to Phase III, as of 2010, is 18%. The amount of money spent on Phase II/III trials in 2015 by Large Sponsors (R&D $500M+) was $465,725,000 on average, while Non-Large Sponsors (R&D <$500M) spent $13,352,000 on average. The entire process of a drug from lab to this point may take approximately 12 to 18 years (but not always), often costing over $1 billion.

Related Pharmaceutical EventsPharmaceutical Conferences

Related Societies

Association of Clinical Research Professionals - ACRPInternational Biopharmaceutical AssociationEuropean Biopharmaceutical EnterprisesAssociation of Clinical Research OrganizationsEuropean Pharmaceutical Union, AACP – American Association of Colleges in Pharmacy, Royal Pharmaceutical Society, Pharmaceutical society of Australia, National Pharmacy Association, Canadian Pharmacists Association

Track 8: Pharmaceutical Analysis

Producing safe and effective formulation is the main goal for Pharmaceutical industry. Hence pharmaceutical industry has great concern towards impurities due to their adverse effects. The trends in pharmaceutical analysis focuses on the modern methods, technology  and tools for control of  related impurities, and faster analysis time, better separation  time and faster method development.

Related Pharmaceutical EventsPharmaceutical Conferences

Related Societies

Applied Pharmaceutical AnalysisJoint Pharmaceutical Analysis GroupAssociation of Clinical Research Professionals - ACRPAssociation of Clinical Research OrganizationsEuropean Pharmaceutical UnionInternational Pharmaceutical Federation (FIP) AACP – American Association of Colleges in Pharmacy, Royal Pharmaceutical Society, Pharmaceutical society of Australia, National Pharmacy Association, Canadian Pharmacists Association, European Pharmaceutical Union (EPU)

Track 9: Pharmacovigilance

It deals with prevention of adverse drug reaction by collection, detection, assessment, monitoring.  It concerns with the identifying hazards associated with pharmaceutical formulation. The advancement associated with pharmacovigilance helps in producing the valid formulation by focusing on the collected data from patients and health care providers. U.S. pharmacovigilance market size was valued over USD 1 billion in 2015, and predicted to witness 10.7% CAGR from 2016 to 2024 to surpass USD 2.5 billion by 2024.

Related Pharmaceutical EventsPharmaceutical Conferences

Related Societies

International Society of Pharmacovigilance (ISOP)Pharmaceutical Information and Pharmacovigilance Association (Pipa), AACP – American Association of Colleges in Pharmacy, Royal Pharmaceutical Society, Pharmaceutical society of Australia, National Pharmacy Association, Canadian Pharmacists Association, European Pharmaceutical Union (EPU)Drug Discovery and Development Interface (DDDI)European Pharmaceutical UnionPharmaceutical Society of AustraliaCanadian Pharmacists Association

Track 10: Regulatory Affairs & Intellectual Property Rights

Regulatory Affairs has a very specific meaning within the healthcare industries. Its regulations are for systematic manufacturing and marketing of safe, efficacious and qualitative drugs. Improving new regulations and adapting to the technology regulatory affairs set new goals and challenges to the pharmaceutical formulation. The global regulatory affairs outsourcing market had a valuation of US$1.9 bn in 2014. The market is expected to expand at a substantial 11.5% CAGR from 2015 to 2023 and rise to a valuation of US$5.7 billion by 2023.

Related Pharmaceutical EventsPharmaceutical Conferences

Related Societies

Regulatory Affairs Professionals Society (RAPS), Association of Clinical Research Professionals - ACRP, AACP – American Association of Colleges in Pharmacy, Royal Pharmaceutical Society, Pharmaceutical society of Australia, National Pharmacy Association, Canadian Pharmacists Association, European Pharmaceutical Union (EPU), Association of Clinical Research OrganizationsPharmaceutical Group of the European Union (PGEU)International Pharmaceutical Federation (FIP)European Association of Employed Community Pharmacists in Europe (EPhEU),

Track 11: Ethics In Pharmacy

Pharmacy is a healthcare profession assisting individual in making the best use of medicine. Ethics are intended to state publicly the principles that form the fundamental basis of the roles and responsibilities of pharmacists. Spending on specialty drugs in 2012 in the United States was about $87 billion. Estimates suggest that it could quadruple by 2020, reaching about $400 billion

Related Pharmaceutical EventsPharmaceutical Conferences

Related Societies

American Society for Pharmacy Law, European Pharmaceutical UnionPharmaceutical Society of AustraliaAACP – American Association of Colleges in Pharmacy, Royal Pharmaceutical Society, Pharmaceutical society of Australia, National Pharmacy Association, Canadian Pharmacists Association, European Pharmaceutical Union (EPU), American Society of Consultant Pharmacists (ASCP), American Society of Consultant Pharmacists Foundation

Track 12: Pharmacy & Pharmacist

Pharmacists are becoming a more integral part of the health care team. Pharmacists do indeed dispense medicines, but first they check for any possible interactions with other medicines or medical conditions. They also instruct patients on how to take the medicines and will inform them about what to do if certain side effects arise. Pharmacy is the healthcare service science and expertise of preparing and dispensing drugs. Pharmacy Modern service includes more traditional and advanced compounding and dispensing medication healthcare. The biggest challenge facing pharmacy is continuing to communicate its role, deliver its value, and be reasonably reimbursed.

The Bureau of Labor Statistics projects a slower-than-average 3 percent employment growth for pharmacists by 2024, with the field adding 9,100 new jobs. Employment of pharmacists is expected to decline slightly in traditional retail settings because more people are having their prescriptions filled online or through mail order.

Related Pharmaceutical EventsPharmaceutical Conferences

Related Societies

Canadian Pharmacists AssociationAmerican Society of Consultant Pharmacists (ASCP), American Society of Consultant Pharmacists FoundationAACP – American Association of Colleges in Pharmacy, Royal Pharmaceutical Society, Pharmaceutical society of Australia, National Pharmacy Association, Canadian Pharmacists Association, European Pharmaceutical Union (EPU),  Indian Pharmacist AssociationEuropean Pharmaceutical UnionPharmaceutical Society of Australia

Track 13: Drug Disposition & Biological Products

Pharmacokinetic studies are more important for therapeutic biologics. Identifying the key factors that govern absorption, distribution, metabolism, and excretion of biologics as therapeutic agents improved the opportunities for the scientists working in drug disposition research field. The European Union (EU) first approved a biologic in 2006, now there are more than 700 biosimilars approved or in the pipeline globally. Analysts expect the worldwide biosimilars market to reach $25 billion to $35 billion by 2020. Generics have larger share of total global medicine spend, increasing from 27 percent ($261 billion) in 2012 to 36 percent ($421 billion) by 2017.

Related Pharmaceutical EventsPharmaceutical Conferences

Related Societies

International Alliance for Biological Standardization (IABS)International Biopharmaceutical AssociationEuropean Biopharmaceutical EnterprisesAssociation of Clinical Research Professionals - ACRPAssociation of Clinical Research Organizations, AACP – American Association of Colleges in Pharmacy, Royal Pharmaceutical Society, Pharmaceutical society of Australia, National Pharmacy Association, Canadian Pharmacists Association, European Pharmaceutical Union (EPU)

Track 14: Good Manufacturing Practices

GMP is Set of guidelines to manufacturers must meet to assure that the products are high quality and safe. GMP covers all aspects of production from the beginning to end of the manufacturing aspects. Introduced latest trends in GMP are risk- based approaches which are to encourage adoption of new technology by pharmaceutical industry.

Pharmaceutical industries are facing hurdles in adopting new technologies quickly.

Related Pharmaceutical EventsPharmaceutical Conferences

Related Societies

European Medicines AgencyCanadian Pharmacists AssociationAACP – American Association of Colleges in Pharmacy, Royal Pharmaceutical Society, Pharmaceutical society of Australia, National Pharmacy Association, Canadian Pharmacists Association, European Pharmaceutical Union (EPU), Indian Pharmacist AssociationPharmaceutical Group of the European Union (PGEU)International Biopharmaceutical AssociationEuropean Biopharmaceutical Enterprises

Track 15: Bio-availability and Bio equivalence

Bio availability is the rate and extent of active drug absorbed and available for action. Assessment of “interchangeability” between the generic and the innovator product is carried out by a study of bioequivalence (BE). During formulation of new entities bio availability and bio equivalents are also prime parameters. Through the conduct of bioavailability and bioequivalence studies, Generic drug products results on average bioequivalence in drug absorption. The top 15 biopharmaceutical products each profits annual revenue of more than $2 billion, with some drugs generating sales of more than $10 billion a year. In 2015 the top NMEs include Pfizer’s Ibrance, J&J’s Darzalex and Gilead’s Genvoya with a cumulative value of $32bn of sales expected in 2020.

Related Pharmaceutical EventsPharmaceutical Conferences

Related Societies

International Biopharmaceutical AssociationEuropean Biopharmaceutical EnterprisesPharmaceutical Society of AustraliaCanadian Pharmacists AssociationPharmaceutical Group of the European Union (PGEU), AACP – American Association of Colleges in Pharmacy, Royal Pharmaceutical Society, Pharmaceutical society of Australia, National Pharmacy Association, Canadian Pharmacists Association, European Pharmaceutical Union (EPU)

Track 16:  Pharma Marketing

A pharmaceutical company is a commercial business licensed to researchdevelopmarket and/or distribute drugs, most commonly in the context of healthcare. The winds of change are blowing through and, in fact, revolutionizing logistics in the global pharmaceutical industry. The prime contributing factors are raising costs, growing risks, changing consumer needs and tightening regulations, globally. Pharmaceuticals represented a US$300 bn-a-year market globally as of 2015, the World Health Organization states. The global pharmaceutical market is expected to surpass US$400 bn by 2018, with the ten largest pharmaceutical companies collectively commanding about a third of the market.

Related Pharmaceutical EventsPharmaceutical Conferences

Related Societies

Pharmaceutical Management Science Association (PMSA)Medical Marketing and MediaInternational Pharmaceutical Federation (FIP)European Association of Employed Community Pharmacists in Europe (EPhEU)International Biopharmaceutical Association, AACP – American Association of Colleges in Pharmacy, Royal Pharmaceutical Society, Pharmaceutical society of Australia, National Pharmacy Association, Canadian Pharmacists Association, European Pharmaceutical Union (EPU)

Track 17: Entrepreneurs’ investment meet

The life sciences sector’s growth correlates highly with countries’ general economic strength and health care spending levels, and both of these vary widely around the globe. In 2015 North America accounted for 48.7% of world pharmaceutical sales compared with 22.2% for Europe. According to IMS Health data, 58% of sales of new drug discovery made during the period 2010–2015 were on the US market, compared with 23% on the European market. Europe is ensuring competitive growth along with other countries.  By 2022, products currently in drug development will account for 17% of sales in Europe. Europe is expected to show a 3% CAGR 2016-22, mainly driven by the launch of new products currently in development. The penetration of biotech products is set to increase from a 24% market share in 2015 to 29% in 2022.

About Conference


ConferenceSeries Ltd invites all the participants across the globe to attend 13th World  Pharma Congress during October 18-19, 2018 Budapest, Hungary. Which includes keynote presentations, plenary sessions, poster presentations and exhibitions. Pharma Congress 2018 is specially designed cluster Pharma conference. The main theme Pharma congress is “Current Technologies & Advancements In Pharmaceutical Field’’ that emphasizes Impact of developing and Marketing Drugs, its registration & approval” which covers a wide range of critically important sessions.


Why to Attend???

Meet Your Target Market with members from around the world focused on learning about Pharma, this is your single best opportunity to reach the largest assemblage of participants from the Pharma community. Conduct demonstrations, distribute information, meet with current and potential Scientists, make a splash with a new research, and receive name recognition at this 2-day Pharmaceutical Event. World-renowned speakers, the most recent techniques, tactics, and the newest updates in Pharmaceutical Sciences fields are hallmarks of this conference.

A Unique Opportunity for Advertisers and Sponsors at this International event:

Target Audience:

  • Professors, Associate Professors, Assistant Professors
  • PhD Scholars
  • Graduates and Post Graduates
  • Directors, CEO’s of Organizations
  • Association, Association presidents and professionals
  • Noble laureates in Health Care and Medicine
  • Bio instruments Professionals
  • Bio-informatics Professionals
  • Software development companies
  • Research Institutes and members
  • Supply Chain companies
  • Manufacturing Companies
  • CRO and DATA management Companies
  • Training Institutes
  • Business Entrepreneur

2018 Highlights:

  • 300+ Participation (70 Industry: 30 Academia)
  • 5+ Keynote Speakers
  • 50+ Plenary Speakers
  • 20+ Exhibitors
  • 14 Innovative Educational Sessions
  • 5+ Workshops
  • B2B Meetings

Past Conference Report

Pharma Congress 2017

12th World Pharma Congress held at Mercure Budapest Buda, Budapest, Hungary during October 16-18, 2017 was systematized on the theme of “Healthcare Policy-Makers And Payers: Key Concerns In Paradigm Shift Of Pharma Industry Trends” and was a successful  significant platform  where eminent keynote speakers from various reputed companies and universities made their resplendent presence and addressed the congress. Moreover, the networking sessions laid the foundation for some time worthy collaborations between many start-up and big industries. The post conference networking lunch session witnessed a number of B2B meetings that are turning up to be mutually beneficial to both the organizations who had gone in for the business meetings.

Pharma Congress 2017 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various new-fangled topics. This congress not only brought forward the latest developments in the field but also provided solutions to the numerous challenges encountered in developing.

Conference Series would like to convey a warm gratitude to all the Honourable guests, Keynote Speakers, Delegates, and Media Partners for their participation in Pharma Congress 2017.

We on behalf of the conference specially thank the media partners for their wonderful marketing of the event. Conference Series LLC also took the privilege of felicitating Pharma Congress 2017 Organizing Committee, Keynote Speakers, Chair and Co-Chairs whose support made conference a great success.

With the enormous feedback from the participants and supporters of Pharma Congress 2017, we are glad to announce 18th World Pharma Congress during October 18-19, 2018 at Warsaw, Poland.


Past Reports  Proceedings  Gallery  

To Collaborate Scientific Professionals around the World

Conference Date October 18-19, 2018

For Sponsors & Exhibitors

[email protected]

Speaker Opportunity

Supported By

Journal of Pharmaceutical Care & Health Systems Clinical Pharmacology & Biopharmaceutics Journal of Developing Drugs

All accepted abstracts will be published in respective Conferenceseries International Journals.

Abstracts will be provided with Digital Object Identifier by


Past Affiliations

Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos